Trials / Completed
CompletedNCT04440059
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
A Multicenter, Open Clinical Trial to Evaluate the Safety and Efficacy of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia (WM)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R WM will be evaluated in approximately 44 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-022 | ICP-022 at a dose of 150mg PO QD |
Timeline
- Start date
- 2019-08-10
- Primary completion
- 2024-01-09
- Completion
- 2024-01-09
- First posted
- 2020-06-19
- Last updated
- 2024-04-18
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04440059. Inclusion in this directory is not an endorsement.